X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
Details:
Livtencity (maribavir), Phosphotransferase pUL97 inhibitor has been approved by the National Medical Products Administration of China for the treatment of adult patients with Post-transplant CMV Infection/Disease.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: LIVTENCITY
Highest Development Status: Phase IVProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 21, 2023
Details:
LIVTENCITY (maribavir), an orally bioavailable anti-CMV compound, is the first and only antiviral agent that targets and inhibits the UL97 protein kinase and its natural substrates.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
LIVTENCITY (maribavir), an orally bioavailable anti-CMV compound, is the first and only antiviral agent that targets and inhibits the UL97 protein kinase and its natural substrates.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 11, 2022
Details:
Positive Opinion Based on Phase 3 SOLSTICE Study Demonstrating Maribavir (livtencity) Was Statistically Superior to Conventional Therapies at Study Week 8, for Primary Endpoint.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 16, 2022
Details:
Data include exploratory analysis showing Livtencity treated patients with post-transplant cytomegalovirus infections/disease had reductions in hospitalizations (34.8%) and length of hospital stay (53.8%) compared to those treated with conventional antiviral therapies.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 22, 2022
Details:
LIVTENCITY (maribavir), an orally bioavailable anti-CMV compound, is the first and only antiviral agent that targets and inhibits the pUL97 protein kinase and its natural substrates.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: Livtencity
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2021
Details:
The results of the SOLSTICE trial are promising and show that maribavir may help with post-transplant CMV viremia, including cases of drug-resistance for which there is an unmet need.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: SHP620
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SHIRE LLC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2021
Details:
More than three times as many transplant recipients with confirmed resistant cytomegalovirus (CMV) infection at baseline receiving the investigational drug Maribavir achieved cmv viremia clearance compared to conventional antiviral therapies.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 15, 2021
Details:
More than twice as many transplant recipients with R/R CMV infection/disease treated with maribavir achieved confirmed CMV viremia clearance at Study Week 8, the study’s primary endpoint, as compared to 23.9% of those on conventional antiviral therapies.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2021
Details:
Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection met its primary endpoint.
Lead Product(s): Maribavir
Therapeutic Area: Infections and Infectious Diseases Product Name: TAK-620
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 04, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
